Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

Br J Dermatol. 2018 Jul;179(1):210-212. doi: 10.1111/bjd.16379. Epub 2018 Apr 25.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Observational Study

MeSH terms

  • Adult
  • Age Factors
  • Anti-Allergic Agents / administration & dosage*
  • Chronic Disease / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Resistance
  • Female
  • Humans
  • Middle Aged
  • Omalizumab / administration & dosage*
  • Retrospective Studies
  • Treatment Outcome
  • Urticaria / drug therapy*
  • Urticaria / pathology

Substances

  • Anti-Allergic Agents
  • Omalizumab